Form 4: NeuroMetrix Director Fluegel Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Director Bradley M. Fluegel reports the vesting of restricted stock units and subsequent stock transactions at NeuroMetrix, Inc.
Summary
- On April 30, 2024, NeuroMetrix, Inc. Director Bradley M. Fluegel vested 5,396 restricted stock units (RSUs) which converted into common stock.
- These RSUs were granted on August 4, 2023, and vested 100% on April 30, 2024.
- The vesting price was $4.37 per share.
- Following the transaction, Fluegel directly owns 8,634 shares of NeuroMetrix common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-08-04 | Reporting person was granted 43,165 restricted stock units prior to the reverse stock split. |
| 2023-11-21 | Reverse stock split of the Issuer's common stock at a ratio 1-for-8, effective as of this date. |
| 2024-04-30 | Date of transaction: vesting of restricted stock units and conversion to common stock. |
| 2024-05-02 | Date of signature on the Form 4 filing. |
Keywords
NeuroMetrix, Fluegel, Director, RSU, Stock, Vesting, NURO, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.